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Abstract The amount of information produced by genomic
sequencing is vast, technically complicated, and can be diffi-
cult to interpret. Appropriately tailoring genomic information
for non-geneticists is an essential next step in the clinical use
of genomic sequencing. To initiate development of a frame-
work for genomic results communication, we conducted eigh-
teen qualitative interviews with oncologists who had referred
adult cancer patients to a matched tumor-normal tissue geno-
mic sequencing study. In our qualitative analysis, we found
varied levels of clinician knowledge relating to sequencing
technology, the scope of the tumor genomic sequencing study,
and incidental germline findings. Clinicians expressed a per-
ceived need for more genetics education. Additionally, they
had a variety of suggestions for improving results reports and
possible resources to aid in results interpretation. Most clini-
cians felt genetic counselors were needed when incidental
germline findings were identified. Our research suggests that
more consistent genetics education is imperative in ensuring
the proper utilization of genomic sequencing in cancer care.
Clinician suggestions for results interpretation resources and
results report modifications could be used to improve commu-
nication. Clinicians’ perceived need to involve genetic coun-
selors when incidental germline findings were found suggests
genetic specialists could play a critical role in ensuring pa-
tients receive appropriate follow-up.
Keywords Genomics .Medical oncology . Cancer
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Introduction
The development of faster and less expensive whole genome
and whole exome sequencing techniques allows for greater
clinical integration of genomic testing. In oncology, sequenc-
ing of tumor tissue with the goal of identifying actionable
mutations for personalized treatments is a part of clinical can-
cer care. Recent national attention driven by the Precision
Medicine Initiative will likely continue to spur the expansion
of this type of precision medicine (Le Tourneau et al. 2012;
The White House 2015). The expanded use of genomic tech-
nologies in oncology brings with it several complex compu-
tational and evidentiary challenges, creating questions about
how to properly incorporate genomic sequencing (GS) results
into clinical practice (Bombard et al. 2013a, b).
The amount of information produced by GS is vast, techni-
cally complicated, and often difficult to interpret. Even highly
specialized clinicians have difficulty translating the data for
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medical decision-making (Meric-Bernstam et al. 2013).
Numerous studies have demonstrated that non-geneticists order-
ing GS often have incomplete and/or inaccurate ideas regarding
implications of results for a patient and his/her treatment (Frey
et al. 2012;Haga et al. 2012;Houwink et al. 2012;Klitzman et al.
2013). Efforts to standardize return of results to patients and
physicians – including which results to report and how to format
the results report – raise ethical and legal questions (Dorschner
et al. 2014; Garraway 2013; Van Allen et al. 2013).
Understanding how to appropriately tailor genomic information
to enable use by non-geneticists is an essential next step in the
further integration of GS for clinical use (Green et al. 2011).
We conducted qualitative interviews with clinicians who
had referred patients to a tissue based tumor/normal GS study
(Robinson et al. 2013; Roychowdhury et al. 2011) in order to
guide the development of a model for GS results communica-
tion that maximizes benefits to both the ordering clinician and
the patient. Our aim was to explore clinicians’ understanding
of the tumor sequencing study, motivations for enrolling pa-
tients, and their perceived barriers to the successful integration
of GS information into cancer treatment.
Materials and Methods
Study Population and Recruitment
Between May 2011 and September 2013, 58 physicians re-
ferred patients to the MI-ONCOSEQ (The Michigan
Oncology Sequencing) Project at the University of Michigan
Health System (UMHS) Comprehensive Cancer Center. This
study provides comprehensive tumor GS analysis for adult pa-
tients with advanced or refractory cancer in order to identify
genetic mutations that could inform future therapeutic choices.
Tumor biopsy, along with matched normal tissue and blood
samples, are subjected to whole-exome sequencing, tran-
scriptome sequencing, and low-pass whole-genome sequenc-
ing as needed (Roychowdhury et al. 2011). We divided these
providers into one of five possible Bbins^ in order to survey
clinicians from a variety of backgrounds: Bin 1) Non-UMHS
clinicians currently practicing at community institutions, Bin 2)
Non-UMHS clinicians currently practicing at academic institu-
tions, Bin 3) UMHS clinicians who had referred 1–2 patients
into the GS study, Bin 4) UMHS clinicians who had referred 3–
9 patients into the GS study, and Bin 5) UMHS clinicians who
had referred 10+ patients into the GS study. We chose to clas-
sify clinicians into academic and community practice bins as
we postulated that clinicians from these two populations would
have differences in terms of their education and experience
with clinical genetics in medicine. Additionally, we hypothe-
sized that clinicians who had referred more patients to the study
would have a more accurate understanding of the study aims.
Our goal for this qualitative study was to interview a minimum
of two physicians per bin to ensure representation from the
various clinical backgrounds and experience.
We sent a single recruitment e-mail containing the in-
formed consent document to eligible clinicians for whom e-
mail addresses could be located (n = 52). Interviews were
conducted by a single investigator (CMW) between
November 2013 and June 2014 and were in-person (UMHS
clinicians) or by telephone (non-UMHS clinicians).
Study Design
Interviews focused on three topics: 1) cancer treatment deci-
sions; 2) gene mutations, GS, and their relationship to cancer;
and 3) expectations for, and communication of, GS results. The
interview guide (see Appendix 1 in Supplementary Material)
was structured using elements of the Bmental models^ approach.
This approach has been used by public health researchers and
involves semi-structured interviews to explore the conceptual
models that patients and providers use to make sense of infor-
mation about health risks (Downs et al. 2008; Morgan and
Millett 2002; Zikmund-Fisher et al. 2013). Piloting of the inter-
view guide took place in the summer of 2013, and revisions
were made based on feedback from practicing clinical cancer
geneticists and cancer genetic counselors. This study was judged
exempt by the institutional review board at the University of
Michigan in August 2013 (HUM00078489).
Analysis
Each interview was recorded and transcribed (CMW). Clinicians
were asked to avoid identifying themselves or their patients dur-
ing the interview. To further ensure confidentiality, all transcripts
were de-identified. In order to ensure the accuracy of the tran-
scripts, a team member (CMW) checked each one for fidelity
with the recordings. Following a phenomenographic framework,
we began our analysis by reading through the transcripts and
identifying global themes (Larsson and Holmström 2007).
These themes became the core codes. Using the core codes as
a framework, two study teammembers (CMW,KAR) coded two
transcripts in parallel to identify further trends and patterns
existing within the core codes and created the initial draft of the
codebook. All study team members reviewed and edited the
initial draft of the codebook to create the finalized version, which
was then used to code all transcripts (CMW). All coding was
performed using Dedoose data analysis software v.5.1 (www.
dedoose.com).
Results
Fifty-two of 58 (89.7%) eligible clinicians were e-mailed a
study invitation. Six eligible clinicians were not contacted be-
cause email addresses were not available. Nineteen clinicians
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responded to the study invitation (36.5%), and 18 (34.6%) were
interviewed. One respondent was not interviewed due to sched-
uling conflicts. We achieved our goal of interviewing at least
two clinicians from each of the five bins (Table 1). Of physi-
cians interviewed, 16/18 (89%) worked at academic centers; 6/
18 (33%) held MD/PhDs; and 10/18 (56%) finished medical
school more than 20 years ago (Table 2).
Following iterative analysis of all transcripts, the finalized
draft of the codebook included 27 core codes, with five key
emerging themes: comprehension of genomic technology,
conflicting goals, results reporting, education, and interpreta-
tion. For additional representative quotes for each theme see
Supplemental Table 1.
Theme 1: Comprehension of Genomic Technology
Of clinicians who discussed the genome sequencing technol-
ogy utilized within the MI-ONCOSEQ GS study (n = 10),
half exhibited a high level of understanding of the study’s
sequencing technology (n = 5), while half (n = 5) expressed
a lack of understanding. Clinicians who expressed a lack of
understanding felt they did not have enough education about
the technology to fully understand it, which at times impeded
their ability to fully comprehend and communicate the
results.
B… you start to read the statistics section and/or the
methods section of a lot of the manuscripts that utilize
the same techniques or technology and after the first
sentence you’re lost…I mean, I have a PhD and I don’t
understand a lot of the biology behind how the DNA is
captured and how the actual sequencing works and how
the statistics are used to determine biologically impor-
tant versus a biologically irrelevant abnormality that
was identified…we’re not educated enough to under-
stand that.^ SUBJECT 2, BIN 4
Of the five clinicians lacking understanding of the technol-
ogy, two expressed misconceptions related to what the tech-
nology was capable of detecting, and these misconceptions
led to overestimates about the scope of the GS study and the
types of results that could be returned. The quotation below
illustrates how a clinician has overestimated the ability of the
study to screen and identify clinical trials that may be appro-
priate for the patient.
B…we can refer them other places for other trials, but
again, the trial is only as good as this [study]. This
[study] hopefully would encompass all trials, or that’s
the idea… you may have a thousand druggable targets,
but each individual trial I could send someone to would
only test one of those drugs. This [study] should be able
to figure out…everything about the patient.^ SUBJECT
10, BIN 3
Theme 2: Conflicting Goals
Some clinicians (n = 3) perceived discordance between
the goals of the GS study’s basic scientists and the
Table 1 Study population and response rate
Bin Total number
of clinicians
Total number of
clinicians contacted
Number of
clinicians interviewed
Response rate
Bin 1 (Non-UMHSa physician working in community hospital) 4 2 2 100%
Bin 2 (Non-UMHS physician working in an academic hospital) 13 12 3 25%
Bin 3 (UMHS physician, referred 1–2 patients) 24 21 7 33%
Bin 4 (UMHS physician, referred 3–9 patients) 9 9 4 44%
Bin 5 (UMHS physician, referred 10+ patients) 9 8 2 25%
Total 58 52 18 35%
aUMHS = University of Michigan Health System
Table 2 Demographic information of clinicians interviewed
Clinician characteristics Proportion of interviewed
clinicians (n = 18)
Percentage
Educational background
Doctor of medicine (MD) 18 100%
Additional advanced degrees 6 33%
Years since medical school
< 5 0 0%
5–10 3 17%
11–20 5 28%
21–30 4 22%
31+ 6 33%
Specialty
Medical oncology 12 67%
Hematology/oncology fellow 2 11%
Other 4 22%
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referring clinicians, mainly related to differing expecta-
tions regarding translation of results into clinical care,
with clinicians having lower expectations about the like-
lihood of GS results impacting patient care. These clini-
cians acknowledged that decreasing this discordance
could positively impact the translation of the sequencing
results for clinicians in the results report.
B…I want to comment that the sequencing side of it
or the lab side of it… does a wonderful job of
looking at the literature but they have no concept
of how this might be used or useable in the patient.
So there’s this gulf even with that attempt at com-
munication from both sides…the basic scientists
have no concept of what it takes to put a drug into
a person. And the clinician struggles a little bit with
trying to understand some of the gobbly-goo that the
scientists talk about.^ SUBJECT 8, BIN 5
Theme 3: Results Reporting
Clinicians had variable views on the best structure for the
results report (Mody et al. 2015; Roychowdhury et al.
2011). Multiple clinicians (n = 6) expressed a desire for
the results report to include more detailed information re-
garding the specific genetic mutations identified and their
potential involvement in the patient’s cancer development.
BSo the fact is, it’s too hard for me, if they basically say,
‘Well, here’s the mutations, good luck’. Realistically,
physicians are going to be more reluctant to refer pa-
tients if it just creates lots of work for them to try and
figure out okay, where on God’s green earth am I going
to get this drug?^ SUBJECT 1, BIN 3
Some clinicians (n = 4) expressed a desire for more
detailed and specific information linking potentially ac-
tionable mutations with specific clinical trials. However,
one clinician worried about the reports including too
much clinical advice.
BThe report sometimes goes a little too far in trying
to suggest clinical approaches to the patient’s man-
agement given that it’s not really written by oncolo-
gists with any expertise in the particular disease…It
worries me a little bit that reports like that may get
out…to the general public…or even the patient who
may say, ‘Well, why didn’t you treat me with this
drug that this says it should work?’ and then having
to explain that I don’t necessarily agree with the
report.^ SUBJECT 4, BIN 4
Theme 4: Genomics Education
When asked what resources could be used to help clinicians
understand and properly interpret GS results, some clinicians
(n = 6) indicated a need for education regarding genetics/ge-
nomics. Other resources clinicians suggested could be useful
included access to the study team (n = 6), links to online
resources (n = 4), resources to help match/facilitate patient
enrollment in clinical trials (n = 2), and access to genetic
counselors (n = 3) and other specialists (n = 2) as needed based
on the results of the testing (Fig. 1). Several clinicians (n = 8)
stated that they expected oncologists working in an academic
setting to have a higher degree of exposure and understanding
of cancer genomics, but were less confident in the abilities of
clinicians working in non-academic settings.
BI would see it as a problem if this becomes more of a
standard for [the] wide oncology community because…
frankly, I would not trust a community oncologist to
order this test or to interpret it because… they are not
there. This is something that they had in their…cancer
bio or molecular biology or pathology in med school but
they are so far out….^ SUBJECT 5, BIN 3
Another clinician pointed out the challenges of translating GS
findings for patients and avoiding potential misconceptions.
B… I’ve had a number of questions from patients, espe-
cially after the Angelina Jolie thing…I start talking
about EGFR mutations and ALK mutations and your
tumor has an EGFR mutation they look at their daugh-
ter… in the room. I say, ‘This is not something that you
passed on to your daughter… this is only in your cancer.
Fig. 1 Number of clinicians who suggested each resource when asked
what resources could aid clinicians in the interpretation and disclosure of
genome sequencing results
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It’s not heritable.’ And you have to make sure that you
use the right words because people don’t understand a
lot of this stuff… and I don’t have a lot of training in
that…and so how do I talk to patients about that is
becoming an important issue, but I kind of figured out
how to get them clear on that fact…it’s important for
people to understand that issue, germline versus somat-
ic mutations.^ SUBJECT 3, BIN 4
Theme 5: Germline Results Interpretation
Clinicians recognized the potential complications associated
with identification of incidental germline findings (IGFs).
Many (n = 6) expressed a lack of clarity related to the types
of IGFs that could be returned. Others (n = 11) expressed
discomfort in communication of those results to patients, es-
pecially in regards to germlinemutations related to non-cancer
conditions. When asked if there are any results that clinicians
would prefer not to receive, one respondent stated:
‘I don’t think so. Well I think some… if we are just talking
about the cancer side, I don’t think so. I think some
clinicians may… not want to deal with the non-cancer
genetic information.’^ SUBJECT 13, BIN 2
Most of the clinicians interviewed acknowledged the need
for genetic counselor (GC) involvement when IGFs were
identified (n = 12).
B… if I were to order the test I would probably need to
talk to somebody like you [a genetic counselor] before…
I convey the message because… there are undoubtedly
going to be results that I don’t know the implication of…
I’m not saying that because I ordered the test I should be
the one explaining it…I guess actually as I’m thinking
about this, the results as a whole, when you start think-
ing about germline mutations, probably are best
discussed by a genetic counselor who can talk about
all the results and not just something specific to the
cancer. I actually hadn’t thought about that.^
SUBJECT 11, BIN 3
Discussion
Our qualitative study examined the understanding and ex-
pectations related to genomic sequencing (GS) among clini-
cians referring patients with cancer to a tissue tumor/normal
GS study. One of the most challenging aspects of incorporat-
ing GS into clinical practice is effective results interpretation
and disclosure, which can be confounded by many factors.
These interviews offer valuable insight on a number of key
issues that can be used to further develop the model of GS
results communication in a precisionmedicine context. Since
the time these interviews were conducted (November 2013
through June 2014) the use of somatic tumor testing with the
goal of identifying therapeutic targets specific to a patient’s
unique tumor profile has become much more widespread. In
a recent study of cancer genetic counselors examining their
current practices with regards to tumor testing, 87.6% report-
ed that their institutions were using tumor testing, though
only 6.7% did this routinely (Goedde et al. 2017). While
the current study conducted interviews in the context of ex-
amining clinician understanding and experiences within a spe-
cific research study, the overall objectives of both the research
study and the clinical tumor testing taking place today overlap
significantly. For example, the FoundationOne website states
that BThe test is designed to provide physicians with clinically
actionable information to guide treatment decisions for pa-
tients based on the genomic profile of their disease^ (https://
www.foundationmedicine.com/genomic-testing/foundation-
one). Thus, we believe that many of the opinions and
suggestions of the clinicians interviewed as a part of this
study are applicable to the wider context of the clinical
somatic tumor testing that is currently being utilized.
Many of our clinicians expressed a need for increased
genomics education, and many also expected academic on-
cologists to have higher levels of genomic knowledge than
oncologists working in community settings. This variability
in knowledge concerning genomic technology, even within
an academic cancer center, aligns with previous findings
and indicates this lack of knowledge is not unique to com-
munity oncologists (Gray et al. 2014). Perhaps more impor-
tantly, misconceptions related to the technology led to mis-
understandings about potential results and inaccurate ideas
about the scope of research. A lack of genomics knowledge
has been consistently identified as a barrier to the adoption
and use of genetic/genomic testing, and thus could lead to
provider-based variation in the use of clinical GS (Cox et al.
2012; Delikurt et al. 2015; Freedman et al. 2003; Hamilton
et al. 2014; Khoury et al. 2012; Scheuner et al. 2008). While
it is possible that the clinicians’ apparent misunderstanding
of the GS technology and goals of the GS study could be
unique to this particular study, we believe a more likely
explanation is that many of the misunderstandings clini-
cians expressed are tied to the deeper and more widespread
problems relating to clinician misunderstanding of genetics
in general. Significant work has been done in attempts to
examine different educational programs aiming to increase
clinician knowledge about genetics, however, it is clear that
this is an area that remains a large challenge across disci-
plines (Bell et al. 2015). While an in-depth review of differ-
ent educational strategies that have been employed to en-
hance clinician understanding of genetics is beyond the
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scope of this research, we did ask clinicians what resources
they thought would be helpful in increasing study compre-
hension and results interpretation. Their recommendations
included online resources (e.g. linking mutation informa-
tion directly to online data), direct access to the study team,
and access to genetic counselors/other specialists in the
event of an IGF.
Of note, at the time these interviewswere conducted, a total of
four clinicians practicing in the community setting had referred
patients to the research study, and of those, email addresses were
available for two. Both of these clinicians agreed to be
interviewed. The paucity of community physicians available
for interview is therefore reflective of the makeup of clinicians
referring patients to this research study within an academic med-
ical center and speaks towards a broader inequality in terms of
patients treated in academic versus community settings and en-
rollment in clinical trials. Significant research has been done
examining clinical trial enrollment and factors such as race,
age, socioeconomic status, and treatment setting have all been
shown to impact levels of clinical trial enrollment (Behrendt et al.
2014; Goss et al. 2009; Sateren et al. 2002). In 2007 the National
Cancer Institute (NCI) created a program, the NCI Community
Cancer Centers Program (NCCCP), with the aim of improving
patient access to state-of-the-art care in community settings
(Clauser et al. 2009; Copur et al. 2016; Hirsch et al. 2016).
Previous studies, focused on genetics services, have found that
clinicians working in rural settings may be more likely to lack
awareness regarding the availability of genetic services. In one
study, only 1% of patient referrals to a hereditary breast cancer
program came from rural areas (Delikurt et al. 2015; Koil et al.
2003). This speaks to a larger issue regarding disparities in access
to genetics services between patients living in urban/suburban
settings compared with those in rural settings, which we discuss
in further details below.
There is no consensus about which GS results to report and
how reports should be formatted (Van Allen et al. 2013). Our
study found thatmany clinicians expressed a desire for the results
report to contain detailed information regarding the specific mu-
tations identified, their potential involvement in the patient’s can-
cer development, and suggestions for therapies/clinical trials.
Clinicians also raised the concern that reports should not be too
prescriptive in their interpretation and recommendation. Many
clinicians associated a desire for a more detailed report with a
high level of personal interest in the underlying genetics/geno-
mics, however this may be unique to our study population of first
adopters in a novel GS study in an academic institution.
Interviewees acknowledged that many clinicians would likely
prefer a one-page report outlining major findings, an idea consis-
tent with other studies examining the format of genomic reports
(Dorschner et al. 2014).
Clinicians felt the basic scientists on the MI-ONCOSEQ pro-
ject were largely focused on identification of targetablemutations
that could alter a patient’s clinical management and failed to
understand the practicalities involved in getting a particular drug
to a specific patient (e.g., access and availability of suggested
treatments), leading to frustration about the lack of translation
of the GS results. Better alignment of the goals of basic scientists
and referring physicians on GS studies is an integral step in
developing the proper framework for the return of results neces-
sary for the successful translation of GS for clinical care. Of note,
all clinicians who referred a patient to this sequencing studywere
invited to attend a Precision Medicine Tumor Board, consisting
of a multidisciplinary team of oncologists, molecular and clinical
geneticists, genetic counselors, bioinformaticians, pathologists,
and bioethicists (Everett et al. 2014). Other centers have also
begun to develop similar precision medicine-focused tumor
boards to specifically review tumor testing results (Gunderson
et al. 2016; McGowan et al. 2016; Schwaederle et al. 2014).
These types of multidisciplinary conferences may present anoth-
er opportunity for clinicians to increase their education about
tumor testing and increase direct interactions between basic sci-
entists and clinicians, which could aid in improved communica-
tion and alignment in the perceived goals and outcomes of tumor
testing. Additionally, in an effort to improve clinician knowledge
at academic and community centers alike, we suggest that it may
also be useful for hospitals that have active molecular tumor
boards to open up these discussions to clinicians at other institu-
tions (e.g. via teleconference or web conference) and allow these
clinicians to submit their own cases for discussion. Further de-
velopment of web-based tumor boards, like the series of BVirtual
Molecular Tumor Boards^ webinars currently being broadcast
by the Association of Community Cancer Centers, also represent
additional areas of growth that could allow for further dissemi-
nation of education about molecular tumor testing (http://accc-
cancer.org/resources/virtual-tumor-boards.asp). Future research
could examine the perceived utility of providing detailed
clinical management suggestions on reports, most specifically
in situations where the laboratories writing the reports may
have no or very little clinical information about the patient.
Mandating the involvement of genetics specialists when
ordering germline testing for hereditary cancer syndromes
has generated controversy, with the American Society of
Clinical Oncology positing that requiring genetic specialist
involvement would limit the ability of oncologists to deliver
proper care to their patients (American Society of Clinical
Oncology 2013; Cigna 2017). Though there certainly are
non-genetic specialists capable of providing high-quality
care in relation to discussions of hereditary cancer, recent
studies have demonstrated differences in the quality of ser-
vices delivered by clinicians who are genetics specialists ver-
sus those who are not (Armstrong et al. 2015; Cragun et al.
2015). When discussing the possible results that could be
produced by tumor GS, our participants expressed discom-
fort in communicating IGFs to patients. Though the MI-
ONCOSEQ project is only returning pathogenic germline
mutations identified in known cancer predisposing genes,
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clinicians discussed the potential complexities involved in
the incidental discovery of conditions such as sickle cell ane-
mia, Huntington’s disease, or issues such as non-paternity
(Everett et al. 2014). Some clinicians said they would prefer
not to receive incidental results that did not relate to heredi-
tary cancer predisposition, while others stated they would be
willing to disclose those results to patients, but would then
refer them to the necessary specialist. They acknowledged
the need for genetic counselor involvement when IGFs were
identified in order to aid clinicians in properly communicat-
ing results to patients and to help ensure appropriate follow-
up testing. Some clinicians admitted that they had not asso-
ciated the GS study with the identification of germline vari-
ants, although these findings are possible through both
tumor/matched normal tissue GS (as in this study) or indi-
rectly through somatic mutation testing of tumor tissue
(Bombard, Robson, et al. 2013; Raymond et al. 2016). This
is an important finding as a recent American Society of
Clinical Oncology policy statement advocates for a pre-test
discussion on the potential risks of identifying incidental and
secondary germline information in tumor sequencing (Robson
et al. 2015). Additionally, one of the recommendations within
the recently released Cancer Moonshot Blue Ribbon Panel
Report related to prevention and early detection of cancer
emphasized the importance of identifying individuals with a
genetic predisposition to cancer (National Cancer Institute
2016). Recognizing individuals whose tumor sequencing re-
sults could indicate a possible germline mutation related to a
hereditary cancer syndrome may serve as an important chan-
nel for identifying these patients and allowing for more per-
sonalized cancer risk estimates and screening/surveillance rec-
ommendations for them and their family members.
The findings of this study suggest that involvement of a
genetics specialist benefits both clinicians and patients and
thus serves an important role in GS results communication
(see Everett et al. for a review of genetic counselors’ work
within the MI-ONCOSEQ project)(Everett et al. 2014). We
acknowledge that the limited number of genetic specialists
means it is unrealistic to mandate their direct involvement
on all GS projects. We suggest the involvement of genetic
counselors in the project development plan to specifically ad-
dress how patients should be informed of the potential to
identify incidental and secondary results, and that in situations
where genetic counselors cannot be directly involved in GS
projects, steps should be taken to ensure that all patients found
to have actionable IGFs receive the proper follow-up and a
referral to an appropriate genetics clinic. As noted above, there
are known disparities in terms of access to genetic services
between patients in rural versus urban/suburban settings, and
overall the demand for genetic counseling services may soon
exceed the current supply of genetic counselors. While the
genetic counseling community is attempting to combat this
workforce issue in numerous ways, including the
development of more genetic counseling programs and expan-
sion of current programs, it seems likely that other innovations
will be needed to ensure that patients in need of genetic
counseling have access (Pan et al. 2016). For example, tumor
testing companies may consider hiring genetic counselors
who can be available to clinicians to answer questions regard-
ing their patient’s results specifically as it relates to germline
findings. Additionally, given that the lack of awareness of the
availability of genetic specialists has been shown to be a bar-
rier to referral, these company-based genetic counselors could
also aid clinicians in identifying genetic specialists in their
area who they could refer their patient to. Consideration for
alternative genetic counseling delivery models, such as tele-
medicine, could also provide a possible option for patients
who may not have direct access to a genetic counselor. Early
research on telegenetic counseling models have shown similar
results in terms of psychosocial outcomes and patient satisfac-
tion between patients receiving telephone counseling versus
those receiving in-person counseling, and thus represents a
promising alternative for patients (Buchanan et al. 2015,
2016). It is also important to note that additional education
regarding tumor testing may be beneficial to both practicing
genetic counselors, as well as for students who are currently in
genetic counseling graduate programs. In the study byGoedde
et al. 63.7% of cancer genetic counselors reported being per-
sonally involved in tumor testing in some capacity, though
notably Bonly 16.5% (16/97) of genetic counselors felt their
institution was completely prepared to handle tumor profiling
results, and only 5.2% (5/97) felt they were personally
completely prepared^ (Goedde et al. 2017). This speaks to-
wards an urgent need within the cancer genetic counseling
community for increased education regarding tumor sequenc-
ing to ensure that our workforce is prepared to handle these
types of referrals when they arrive.
Study Limitations
The current study is not without limitations, the most significant
of which is the small sample size. The views expressed by the
interviewed clinicians may not reflect those of all clinicians cur-
rently using GS in their clinical practice or intending to use it in
the future. Clinicians with a variety of institutional and educa-
tional backgrounds were interviewed; however, the majority of
clinicians were practicing within an academic center. As noted
above, the small number of clinicians interviewed within the
community setting is reflective of the population of clinicians
who had referred patients to the study at the time interviewswere
conducted, though certainly does indicate that the views of com-
munity clinicians are likely underrepresented by this analysis.
Additionally, because the tumor sequencing study is a pilot, it
is expected that the referring clinicians who were interviewed
may be more interested in the integration of GS into clinical
practice than non-referring clinicians. This self-selection may
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be evenmore pronounced among the clinicians who agreed to be
interviewed.
Policy Implications and Research Recommendations
In summary, through iterative analysis of interviews conducted
with clinicianswho referred patients to a tumor sequencing study,
we gained valuable insight on a number of key issues related to
the use ofGS that could be used to further develop amodel of GS
results communication. Variable levels of clinician knowledge
suggest that the development of accessible educational programs
focused on genomics for clinicians is an imperative step in en-
suring the proper utilization of GS in cancer care. In general,
clinicians desired more in-depth interpretation of the mutation
data, and more specific, detailed information linking specific
mutations with appropriate clinical trials (with practical assis-
tance as necessary in facilitating patient enrollment in trials for
which they are putatively eligible). Further research on refining
the depth and detail in tumor testing reports to facilitate clinician
understanding and ensure clear communication of results is es-
sential, especially as tumor testing becomes more widespread.
Finally, clinicians recognized the specialized communication
skills required for discussions of IGFs, and we would suggest
that the involvement of genetics specialists, when augmented
with both in-person and online educational resources will help
ensure the accurate and judicious integration of GS results into
clinical practice. Genetic counselors should anticipate receiving
increasing numbers of referrals based on findings from tumor
testing, and educational opportunities to allow genetic counselors
to increase their knowledge in this area represents an urgent need
within our community. This represents a possible area of growth
for the genetic counseling field, and learning how to decipher
tumor sequencing reports and identify mutations found in tumors
that could represent germline mutations will be integral skills for
counselors moving forward. Genetic counselors have an oppor-
tunity, working alongside the oncologists and laboratory scien-
tists at their institutions, to play a key role in establishing a pipe-
line to allow for identification of patients who may benefit from
follow-up germline testing.
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